Tau Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of tau protein pathology in the living brain[1]. tau protein, which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of Alzheimer's Disease and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms[2]. [1:1]
The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging Amyloid-Beta plaques. The first generation of tau PET tracers included: [2:1]
Tau PET tracers bind to: [3:1]
Ideal tau PET tracers should have: [4:1]
Tau PET helps distinguish between:
Tau PET follows the Braak staging of tau pathology:
Tau PET is essential for:
In AD, tau deposition follows a characteristic pattern:
Different tracers show varying binding to:
Tau PET imaging using tracers like [^18F]flortaucipir (FTP) shows distinct patterns in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) that help differentiate these 4R tauopathies from Alzheimer's disease.
In corticobasal syndrome, tau PET shows:
In progressive supranuclear palsy, tau PET shows:
| Feature | CBS | PSP | AD |
|---|---|---|---|
| Temporal lobe | Moderate | Low | High |
| Parietal/occipital | High | Low | High |
| Brainstem | Moderate | High | Low |
| Basal ganglia | High | High | Low |
| Asymmetry | Strong | Mild | None |
Tau PET in CBS/PSP is used for:
The initial tau PET tracers were developed based on amyloid imaging principles:
[^18F]Flortaucipir (AV-1451, Tauvid)
[^11C]PBB3
[^18F]MK-6240
[^18F]RO-948
[^18F]PI-2620
Regional tau PET signal follows the characteristic Braak staging progression:
| Stage | Brain Regions | Clinical Correlation |
|---|---|---|
| I-II | Transentorhinal | Preclinical |
| III-IV | Limbic | MCI/early AD |
| V-VI | Isocortical | Moderate-severe AD |
| Metric | Description | Clinical Use |
|---|---|---|
| SUVR | Standardized uptake value ratio | Regional burden |
| Centiloid-T | Tau-specific centiloid scale | Cross-study comparison |
| Braak ROI | Region-specific staging | Disease staging |
| DVR | Distribution volume ratio | Kinetic modeling |
Diagnostic Utility
Differential Diagnosis
Braak Staging In Vivo
Severity Assessment
Cognitive Decline Prediction
Scanning Protocol
Quality Control
Cross-Sectional Measures
Longitudinal Measures
| Feature | CSF p-tau | Tau PET |
|---|---|---|
| Specificity | High | Very high |
| Spatial resolution | Global only | Regional |
| Disease staging | Limited | Excellent |
| Accessibility | Good | Limited |
Okamura N, et al. Tau PET development. J Nucl Med. 2005. ↩︎ ↩︎
Zhang YW, et al. Tau PET tracers. Mol Neurodegener. 2012. ↩︎ ↩︎
Chien DT, et al. Flortaucipir binding. J Nucl Med. 2013. ↩︎ ↩︎
Johnson KA, et al. Tau PET clinical. Brain. 2016. ↩︎ ↩︎
Brier MR, et al. Tau PET cognition. Lancet Neurol. 2016. ↩︎
Scholl M, et al. Tau PET early detection. Neuron. 2016. ↩︎
Ossenkoppele R, et al. Tau PET differential. JAMA Neurol. 2015. ↩︎
Gordon BA, et al. Tau PET patterns. Alzheimers Dement. 2018. ↩︎
Smith R, et al. Tau PET progression. Brain. 2020. ↩︎
FDA. Flortaucipir approval. 2020. ↩︎
Xia CF, et al. Flortaucipir specificity. J Med Toxicol. 2013. ↩︎
Lowe VJ, et al. Flortaucipir validation. Neurology. 2016. ↩︎
Hansen AK, et al. Flortaucipir off-target. J Nucl Med. 2016. ↩︎
Maruyama M, et al. PBB3 imaging. Neuron. 2013. ↩︎
Perez-Nievas NI, et al. PBB3 non-AD tau. Brain. 2013. ↩︎
Shimada H, et al. PBB3 PSP. J Neurol Neurosurg Psychiatry. 2015. ↩︎
Hashimoto H, et al. PBB3 carbon-11. Ann Nucl Med. 2015. ↩︎
Swaminathan S, et al. MK-6240 characterization. J Nucl Med. 2018. ↩︎
Hostetler ED, et al. MK-6240 properties. J Med Toxicol. 2018. ↩︎
Sur C, et al. MK-6240 kinetics. J Cereb Blood Flow Metab. 2019. ↩︎
Walji AM, et al. RO-948 characterization. J Med Toxicol. 2016. ↩︎
Mueller A, et al. RO-948 off-target. J Nucl Med. 2017. ↩︎
Brendel M, et al. RO-948 test-retest. J Nucl Med. 2020. ↩︎
Song M, et al. PI-2620 tauopathies. Brain. 2019. ↩︎
Hammes J, et al. PI-2620 PSP. Neurology. 2019. ↩︎
Beyer L, et al. PI-2620 clinical. Alzheimers Dement. 2020. ↩︎
Fleisher AS, et al. Tau PET sensitivity. Alzheimers Dement. 2021. ↩︎
Ossenkoppele R, et al. Tau PET specificity. Lancet Neurol. 2021. ↩︎
Sperling RA, et al. Tau PET preclinical. Alzheimers Dement. 2011. ↩︎
Rascovsky K, et al. Tau PET FTD. Lancet Neurol. 2011. ↩︎
Gomperts SN, et al. Tau PET DLB. Neurology. 2016. ↩︎
Passamonti L, et al. Tau PET PSP CBD. Brain. 2017. ↩︎
Braak H, et al. Tau staging. Acta Neuropathol. 2006. ↩︎
Scholl M, et al. Tau PET Braak correlation. Brain. 2016. ↩︎
Harrison TM, et al. Tau PET early intervention. Lancet Neurol. 2021. ↩︎
Brier MR, et al. Tau cognition correlation. Lancet Neurol. 2016. ↩︎
La Joie R, et al. Regional tau cognition. Neuron. 2019. ↩︎
Koychev I, et al. Tau progression prediction. J Prev Alzheimers Dis. 2017. ↩︎
Jack CR Jr, et al. Tau longitudinal prediction. Alzheimers Dement. 2018. ↩︎
Betthauser TJ, et al. Tau accumulation rate. Neurology. 2020. ↩︎
Hansson O, et al. Amyloid-tau prediction. EMBO Mol Med. 2020. ↩︎
Schmidt ME, et al. Tau PET dosimetry. Nat Rev Neurol. 2015. ↩︎
Shcherbakova I, et al. Tau PET protocol. J Nucl Med. 2019. ↩︎
Rahmim A, et al. PET reconstruction tau. Phys Med Biol. 2008. ↩︎
Zhou L, et al. Tau PET motion correction. Alzheimers Dement. 2021. ↩︎
Burger C, et al. PET attenuation correction. Neuroimage. 2009. ↩︎
Landau SM, et al. Tau PET pipeline. Neurology. 2015. ↩︎
Maass A, et al. Tau SUVr methodology. Neuroimage. 2017. ↩︎
Baker JE, et al. Tau composite score. Neurology. 2017. ↩︎
Whittington A, et al. Centiloid-T scale. Alzheimers Dement. 2018. ↩︎
Chen K, et al. Tau longitudinal analysis. Brain. 2018. ↩︎
Zhou Y, et al. Tau voxel-wise analysis. Neurobiol Aging. 2019. ↩︎
Lee G, et al. Tau ROI analysis. Neurobiol Aging. 2019. ↩︎
Hardiman O, et al. Amyloid-tau interaction. Nat Rev Neurol. 2016. ↩︎
Rowe CC, et al. Amyloid negative tau. Ann Neurol. 2010. ↩︎
Hampton OL, et al. Combined amyloid-tau PET. Nat Aging. 2021. ↩︎
Cummings JL, et al. Tau trial selection. Alzheimers Dement. 2023. ↩︎
Aisen PS, et al. Trial enrichment. Lancet Neurol. 2021. ↩︎
McDade E, et al. Stratification biomarkers. Alzheimers Dement. 2023. ↩︎
Mintun MA, et al. Anti-amyloid tau effects. Nature. 2021. ↩︎
Hyman BT, et al. Tau treatment monitoring. Lancet Neurol. 2021. ↩︎
Sevigny J, et al. Tau PET dose-response. Nature. 2016. ↩︎
Ramsden M, et al. Tau endpoints. Ageing Res Rev. 2005. ↩︎
FDA. Accelerated approval tau. 2023. ↩︎
Aisen PS, et al. Disease modification evidence. Nat Rev Neurol. 2022. ↩︎
La Joie R, et al. Tau AD progression. Neuron. 2019. ↩︎
Brier MR, et al. Tau regional patterns. Lancet Neurol. 2016. ↩︎
Farrell ME, et al. Tau advanced AD. Neurobiol Aging. 2018. ↩︎
Shoji M, et al. Tau PET PSP pattern. J Neurol Neurosurg Psychiatry. 2015. ↩︎
Passamonti L, et al. Tau PET PSP. Brain. 2017. ↩︎
Whitwell JL, et al. PSP vs AD tau. Brain. 2013. ↩︎
Alexander RP, et al. CBD tau pattern. Neurology. 2016. ↩︎
Boeve BF, et al. CBD asymmetric tau. Neurology. 2013. ↩︎
Lee SE, et al. Tau CBD PSP differentiation. Brain. 2017. ↩︎
Stern RA, et al. Tau PET CTE. Neuron. 2019. ↩︎
Alosco ML, et al. CTE vs AD tau. Neurology. 2018. ↩︎
McKee AC, et al. CTE biomarker development. Acta Neuropathol. 2020. ↩︎
Lemoine L, et al. Tau PET off-target. Brain. 2017. ↩︎
Su Y, et al. Tau PET partial volume. Neuroimage. 2013. ↩︎
Boellaard R, et al. Tau PET availability. Lancet Neurol. 2015. ↩︎
Cho SH, et al. Tau PET early detection limits. JAMA Neurol. 2015. ↩︎
Villemagne VL, et al. Tau PET floor effect. Lancet Neurol. 2013. ↩︎
Goedert M, et al. Tau species. Neuron. 2019. ↩︎
CMS. Medicare tau PET coverage. 2023. ↩︎
ICRP. PET radiation doses. 2007. ↩︎
OECD. Imaging access disparities. 2023. ↩︎
Leuzy A, et al. Next-gen tau tracers. Alzheimers Dement. 2020. ↩︎
Masliah E, et al. Tau oligomer tracers. Mol Neurodegener. 2016. ↩︎
Veerappan A, et al. Tau theranostics. Theranostics. 2012. ↩︎
Lee G, et al. Tau ML interpretation. Neurobiol Aging. 2019. ↩︎
Zhang D, et al. Tau automated analysis. Alzheimers Dement. 2021. ↩︎
Marinescu M, et al. Tau AI prediction. Nat Rev Neurol. 2020. ↩︎
Janelidze S, et al. Blood tau screening. Nat Med. 2020. ↩︎
Zetterberg H, et al. Combined protocols. Nat Rev Neurol. 2021. ↩︎
Kaye J, et al. Point-of-care imaging. Alzheimers Dement. 2021. ↩︎